scholarly journals The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation

2014 ◽  
Vol 20 (8) ◽  
pp. 1211-1216 ◽  
Author(s):  
Michele L. Donato ◽  
David S. Siegel ◽  
David H. Vesole ◽  
Phyllis McKiernan ◽  
Themba Nyirenda ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

scholarly journals Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

2003 ◽  
Vol 121 (1) ◽  
pp. 104-108 ◽  
Author(s):  
José A. Pérez-Simón ◽  
Rodrigo Martino ◽  
Adrián Alegre ◽  
José F. Tomás ◽  
Angel De Leon ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Association between Regimen Related Toxicity and Acute-Graft-Versus-Host Disease.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5017-5017
Author(s):  
Edward A. Copelan
Keyword(s):  
Graft Versus Host Disease ◽  
Acute Gvhd ◽  
Tissue Injury ◽  
Critical Factor ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Grade Ii ◽  
Grade 3 ◽  
Acute Graft

Abstract Tissue injury resulting from preparative therapy for transplantation is integral to the development of acute graft-versus-host disease (GVHD) according to current theory. If toxicity to normal tissues is a critical factor in the pathophysiology of GVHD, greater degrees of regimen related toxicities should be associated with a higher incidence and greater severity of GVHD. We analyzed 438 patients who underwent allogeneic transplantation from related (n=360) or unrelated (78) donors and who survived > 100 days following transplantation. Patients had received preparative regimens of BuCy (n=340) or BuCyVP16 (n=98). Median age was 36 (range 4–66). There were 263 males and 175 females. This cohort survived a median of 35 months (range 3 months to 20 years). Sixty-eight of these patients had developed (Bearman) grade 3-4 regimen related toxicities. These patients had a 50% incidence of acute GVHD > grade II and a 26% incidence of developing GVHD ≤ grade II, compared to significantly lower incidences of 33% (P=.01) and 14% (P=.02) respectively in the group experiencing < grade 3 regimen related toxicity. Exclusion of patients whose GVHD prophylactic regimens were significantly altered because of toxicity did not significantly influence these results. This data suggest that patients who develop severe regimen related toxicity are significantly more likely to develop severe acute GVHD, supporting a potential pathophysiologic role for tissue injury in the development of acute GVHD.

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

Blood ◽  
2004 ◽  
Vol 103 (11) ◽  
pp. 4362-4364 ◽  
Author(s):  
Henk M. Lokhorst ◽  
Kalung Wu ◽  
Leo F. Verdonck ◽  
Laurens L. Laterveer ◽  
Niels W. C. J. van de Donk ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Complete Response ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Insufficient Response ◽  
Relapsed Myeloma ◽  
Donor Lymphocyte Infusions

Abstract The graft-versus-myeloma (GVM) effect of donor lymphocyte infusions (DLIs) is well established. We now report the outcome of DLI in 54 patients with relapsed myeloma following allogeneic transplantation. Twenty-eight patients (52%) responded, 19 patients (35%) with a partial response and 9 patients (17%) with a complete response. Progression-free and overall survival were 19 and 23 months, respectively. We found that acute and chronic graft-versus-host disease (GVHD) observed in 57% and 47% of patients, respectively, following DLI were the strongest predictors for response. This suggests that targets for GVHD and GVM are identical. In a subgroup analysis, deletion of chromosome 13, as determined by double-color fluorescence in situ hybridization (FISH), had no impact on outcome, indicating that these patients are candidates for early allogeneic transplantation followed by DLI, in case of insufficient response. (Blood. 2004;103:4362-4364)

Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 8028-8028
Author(s):  
Liana Nikolaenko ◽  
Saurabh Chhabra ◽  
Parameswaran Hari ◽  
Amrita Y. Krishnan ◽  
Joshua Ryan Richter
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation

2020 ◽  
Vol 20 (6) ◽  
pp. 407-414 ◽  
Author(s):  
Liana Nikolaenko ◽  
Saurabh Chhabra ◽  
Noa Biran ◽  
Arnab Chowdhury ◽  
Parameswaran N. Hari ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation

2017 ◽  
Vol 23 (8) ◽  
pp. 1295-1302 ◽  
Author(s):  
Abraham S. Kanate ◽  
Parameswaran N. Hari ◽  
Marcelo C. Pasquini ◽  
Alexis Visotcky ◽  
Kwang W. Ahn ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Immune Modulation ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document